We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Cepheid said Aug. 30 it had won a $3.3 million grant from the National Institute of Allergy and Infectious Diseases (NIAID) to develop rapid detection technology for tuberculosis (TB).
The FDA is partnering with the Massachusetts Institute of Technology (MIT) to develop new databases to monitor devices and drugs after they have been approved.
AN Edinburgh-based firm has won a US contract, potentially worth up to £25 million, to distribute its pioneering device which makes it easier to take control of a patient's breathing when they are under anaesthetic.
Mirabilis Medica, a privately held medical device company, announced the initial closing of a $4 million Series A financing that will be used to complete development, testing and introduction of its image-guided High Intensity Focused Ultrasound (HIFU) system for treatment of gynecological diseases.
Stellar Pharmaceuticals, a Canadian pharmaceutical developer and marketer of high quality, cost-effective products for select health care markets, announced that its NeoVisc viscosupplementation therapy has received the CE Mark denoting conformity with European standards for safety and allowing for marketing in European Union countries.
The recent release by the Centers for Medicare and Medicaid Services (CMS) of its final FY07 rule substantially revising the Inpatient Prospective Payment System (IPPS) underscores the need for start-up medical companies and the investors who underwrite them to plan very carefully what markets and treatments they choose to invest in, says leading venture capital firm ONSET Ventures.